Symbols / BIAF
BIAF Chart
About
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 4.68M |
| Enterprise Value | -2.32M | Income | -14.74M | Sales | 6.78M |
| Book/sh | 2.57 | Cash/sh | 1.71 | Dividend Yield | — |
| Payout | 0.00% | Employees | 57 | IPO | — |
| P/E | — | Forward P/E | -1.73 | PEG | — |
| P/S | 0.69 | P/B | 0.40 | P/C | — |
| EV/EBITDA | 0.23 | EV/Sales | -0.34 | Quick Ratio | 3.44 |
| Current Ratio | 3.65 | Debt/Eq | 7.65 | LT Debt/Eq | — |
| EPS (ttm) | -13.83 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | -38.50% | Earnings | 2025-11-14 08:00 | ROA | -71.71% |
| ROE | -245.18% | ROIC | — | Gross Margin | 27.86% |
| Oper. Margin | -158.56% | Profit Margin | -217.50% | Shs Outstand | 4.50M |
| Shs Float | 4.02M | Short Float | 0.90% | Short Ratio | 0.55 |
| Short Interest | — | 52W High | 46.53 | 52W Low | 0.69 |
| Beta | 2.46 | Avg Volume | 103.21K | Volume | 195.15K |
| Target Price | — | Recom | None | Prev Close | $1.10 |
| Price | $1.04 | Change | -5.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.99
Latest analyst target
3. DCF / Fair value
$-16.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.99
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-01 | down | Maxim Group | Buy → Hold | — |
| 2024-07-23 | init | Maxim Group | — → Buy | $6 |
- How a noninvasive lung test eased one heavy smoker’s cancer fears - Stock Titan ue, 17 Feb 2026 13
- BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - Yahoo Finance Wed, 19 Nov 2025 08
- bioAffinity Technologies Updates Investor Presentation Materials Online - The Globe and Mail Wed, 11 Feb 2026 08
- BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth - August 21, 2025 - Zacks Investment Research hu, 21 Aug 2025 07
- bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Business Wire Mon, 09 Feb 2026 13
- WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PR Newswire Wed, 08 Oct 2025 07
- Bioaffinity Technologies stock soars after lung cancer test aids early detection - Investing.com Fri, 26 Sep 2025 07
- BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues - Nasdaq Mon, 07 Apr 2025 07
- bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update - Stocktwits hu, 25 Sep 2025 07
- BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - Yahoo Finance ue, 20 May 2025 07
- 18 awarded patents — bioAffinity's CyPath Lung gains U.S. patent allowance for AI flow cytometry test - Stock Titan hu, 16 Oct 2025 07
- 1-for-30 Reverse Split: bioAffinity Technologies Restructures Shares to Maintain Nasdaq Listing - Stock Titan Wed, 17 Sep 2025 07
- 95% Q3 Growth in CyPath Lung Tests: bioAffinity Technologies Sees 97% YTD Sales Rise - Stock Titan ue, 07 Oct 2025 07
- Early-Stage Lung Cancer Detection: bioAffinity's CyPath Test Proves Value in Critical Patient Cases - Stock Titan Fri, 26 Sep 2025 07
- bioAffinity (Nasdaq: BIAF) Q3 CyPath Lung sales volume up 95%; October 111% above YTD avg - Stock Titan Wed, 05 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 37037 | — | — | Stock Award(Grant) at price 0.00 per share. | ZANNES MARIA | Chief Executive Officer | — | 2025-01-10 00:00:00 | D |
| 1 | 14814 | — | — | Stock Award(Grant) at price 0.00 per share. | GIRGENTI STEVEN | Officer and Director | — | 2025-01-10 00:00:00 | D |
| 2 | 6172 | — | — | Stock Award(Grant) at price 0.00 per share. | EDWARDS JAMES MICHAEL CPA | Chief Financial Officer | — | 2025-01-10 00:00:00 | D |
| 3 | 8641 | — | — | Stock Award(Grant) at price 0.00 per share. | ZANNES TIMOTHY PETER | General Counsel | — | 2025-01-10 00:00:00 | D |
| 4 | 21604 | — | — | Stock Award(Grant) at price 0.00 per share. | REVELES XAVIER TRINIDAD | Chief Operating Officer | — | 2025-01-10 00:00:00 | D |
| 5 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | EDWARDS JAMES MICHAEL CPA | Chief Financial Officer | — | 2024-11-05 00:00:00 | D |
| 6 | 33784 | — | — | Stock Award(Grant) at price 0.00 per share. | KNIGHT PETER S | Director | — | 2024-07-01 00:00:00 | D |
| 7 | 33784 | — | — | Stock Award(Grant) at price 0.00 per share. | DIAMOND STUART | Director | — | 2024-07-01 00:00:00 | D |
| 8 | 33784 | — | — | Stock Award(Grant) at price 0.00 per share. | ZANNES MARIA | Chief Executive Officer | — | 2024-07-01 00:00:00 | D |
| 9 | 33784 | — | — | Stock Award(Grant) at price 0.00 per share. | ANDERSON ROBERT A | Director | — | 2024-07-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -1.04M |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.27 |
| NormalizedEBITDA | -8.33M | -7.63M | -5.82M | -1.48M |
| TotalUnusualItems | 0.00 | 212.26K | -3.84M | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 212.26K | -3.84M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.04M | -7.94M | -8.15M | -6.33M |
| ReconciledDepreciation | 605.64K | 249.59K | 10.18K | 4.82K |
| ReconciledCostOfRevenue | 5.98M | 1.74M | 467.00 | 0.00 |
| EBITDA | -8.33M | -7.63M | -5.61M | -5.32M |
| EBIT | -8.94M | -7.88M | -5.62M | -5.32M |
| NetInterestIncome | -74.86K | 85.01K | -2.49M | -1.00M |
| InterestExpense | 92.47K | 37.12K | 2.53M | 1.00M |
| InterestIncome | 17.61K | 122.13K | 46.71K | 424.00 |
| NormalizedIncome | -9.04M | -7.94M | -8.37M | -3.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.04M | -7.94M | -8.15M | -6.33M |
| TotalExpenses | 18.32M | 10.51M | 4.02M | 2.21M |
| TotalOperatingIncomeAsReported | -8.95M | -7.97M | -4.01M | -2.21M |
| DilutedAverageShares | 404.17K | 291.58K | 149.97K | 90.92K |
| BasicAverageShares | 404.17K | 291.58K | 149.97K | 90.92K |
| DilutedEPS | -22.50 | -27.30 | -54.30 | -69.58 |
| BasicEPS | -22.50 | -27.30 | -54.30 | -69.58 |
| DilutedNIAvailtoComStockholders | -9.04M | -7.94M | -8.15M | -6.33M |
| NetIncomeCommonStockholders | -9.04M | -7.94M | -8.15M | -6.33M |
| NetIncome | -9.04M | -7.94M | -8.15M | -6.33M |
| NetIncomeIncludingNoncontrollingInterests | -9.04M | -7.94M | -8.15M | -6.33M |
| NetIncomeContinuousOperations | -9.04M | -7.94M | -8.15M | -6.33M |
| TaxProvision | 11.65K | 20.99K | 2.46K | 1.95K |
| PretaxIncome | -9.03M | -7.92M | -8.15M | -6.32M |
| OtherIncomeExpense | 129.00 | -27.80K | -1.65M | -3.12M |
| OtherNonOperatingIncomeExpenses | 129.00 | -27.80K | -1.87M | 724.93K |
| SpecialIncomeCharges | 0.00 | 212.26K | 239.20K | |
| OtherSpecialCharges | -212.26K | -239.20K | ||
| GainOnSaleOfSecurity | -4.08M | |||
| NetNonOperatingInterestIncomeExpense | -74.86K | 85.01K | -2.49M | -1.00M |
| InterestExpenseNonOperating | 92.47K | 37.12K | 2.53M | 1.00M |
| InterestIncomeNonOperating | 17.61K | 122.13K | 46.71K | 424.00 |
| OperatingIncome | -8.95M | -7.97M | -4.01M | -2.21M |
| OperatingExpense | 12.33M | 8.76M | 4.02M | 2.21M |
| DepreciationAmortizationDepletionIncomeStatement | 605.64K | 249.59K | 10.18K | |
| DepreciationAndAmortizationInIncomeStatement | 605.64K | 249.59K | 10.18K | |
| ResearchAndDevelopment | 1.78M | 1.72M | 1.52M | 1.14M |
| SellingGeneralAndAdministration | 9.94M | 6.79M | 2.48M | 1.07M |
| GeneralAndAdministrativeExpense | 880.77K | |||
| OtherGandA | 880.77K | |||
| GrossProfit | 3.38M | 791.62K | 4.34K | 0.00 |
| CostOfRevenue | 5.98M | 1.74M | 467.00 | 0.00 |
| TotalRevenue | 9.36M | 2.53M | 4.80K | 0.00 |
| OperatingRevenue | 9.35M | 2.51M | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 519.22K | 313.15K | 279.38K | 90.92K |
| ShareIssued | 519.22K | 313.15K | 279.38K | 90.92K |
| NetDebt | 10.00M | |||
| TotalDebt | 1.50M | 1.58M | 251.75K | 11.36M |
| TangibleBookValue | 422.41K | 2.62M | 11.04M | -15.79M |
| InvestedCapital | 2.79M | 4.86M | 11.30M | -4.43M |
| WorkingCapital | -409.81K | 1.72M | 10.82M | -11.60M |
| NetTangibleAssets | 422.41K | 2.62M | 11.04M | -15.79M |
| CapitalLeaseObligations | 1.31M | 1.58M | 0.00 | |
| CommonStockEquity | 2.60M | 4.86M | 11.04M | -15.79M |
| TotalCapitalization | 2.62M | 4.86M | 11.04M | -15.63M |
| TotalEquityGrossMinorityInterest | 2.60M | 4.86M | 11.04M | -15.79M |
| StockholdersEquity | 2.60M | 4.86M | 11.04M | -15.79M |
| RetainedEarnings | -53.64M | -44.60M | -36.67M | -28.51M |
| AdditionalPaidInCapital | 56.14M | 49.39M | 47.65M | 12.70M |
| CapitalStock | 106.59K | 65.76K | 58.67K | 18.74K |
| CommonStock | 106.59K | 65.76K | 58.67K | 18.74K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.91M | 3.37M | 1.14M | 17.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 806.73K | 1.12M | 0.00 | 4.20M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 4.04M | ||
| LongTermDebtAndCapitalLeaseObligation | 806.73K | 1.12M | 0.00 | 160.18K |
| LongTermCapitalLeaseObligation | 786.55K | 1.12M | 0.00 | |
| LongTermDebt | 20.18K | 160.18K | ||
| CurrentLiabilities | 3.10M | 2.25M | 1.14M | 13.04M |
| CurrentDeferredLiabilities | 24.40K | 33.06K | 0.00 | |
| CurrentDeferredRevenue | 24.40K | 33.06K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 694.47K | 460.17K | 251.75K | 11.20M |
| CurrentCapitalLeaseObligation | 522.80K | 460.17K | 0.00 | |
| CurrentDebt | 171.67K | 251.75K | 11.20M | |
| OtherCurrentBorrowings | 171.67K | 251.75K | 11.20M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.08M | 857.04K | 340.68K | 277.19K |
| PayablesAndAccruedExpenses | 1.31M | 897.56K | 546.26K | 1.56M |
| CurrentAccruedExpenses | 318.88K | 292.77K | 201.21K | 1.33M |
| InterestPayable | 0.00 | 1.12M | ||
| Payables | 987.31K | 604.79K | 345.04K | 230.41K |
| AccountsPayable | 987.31K | 604.79K | 345.04K | 230.41K |
| TotalAssets | 6.51M | 8.22M | 12.18M | 1.45M |
| TotalNonCurrentAssets | 3.82M | 4.25M | 220.44K | 15.07K |
| OtherNonCurrentAssets | 19.68K | 16.06K | 6.00K | 2.50K |
| NonCurrentDeferredAssets | 0.00 | 7.94K | ||
| GoodwillAndOtherIntangibleAssets | 2.18M | 2.24M | 0.00 | |
| OtherIntangibleAssets | 775.14K | 833.47K | ||
| Goodwill | 1.40M | 1.40M | 0.00 | |
| NetPPE | 1.62M | 1.99M | 214.44K | 4.63K |
| AccumulatedDepreciation | -536.25K | -373.12K | -269.18K | -259.00K |
| GrossPPE | 2.16M | 2.37M | 483.62K | 263.63K |
| Leases | 482.36K | 380.25K | 0.00 | |
| OtherProperties | 1.44M | 1.81M | 462.15K | 242.17K |
| MachineryFurnitureEquipment | 229.54K | 174.60K | 21.46K | 21.46K |
| BuildingsAndImprovements | 1.54M | 0.00 | ||
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 2.70M | 3.97M | 11.96M | 1.44M |
| OtherCurrentAssets | 174.63K | 149.16K | 191.82K | 59.30K |
| PrepaidAssets | 248.36K | 171.85K | 340.08K | 16.77K |
| Inventory | 27.61K | 18.48K | 5.54K | 0.00 |
| Receivables | 1.14M | 811.67K | 10.49K | 1.53K |
| OtherReceivables | 27.87K | 29.55K | 10.49K | |
| AccountsReceivable | 1.11M | 782.12K | 0.00 | 1.53K |
| CashCashEquivalentsAndShortTermInvestments | 1.11M | 2.82M | 11.41M | 1.36M |
| CashAndCashEquivalents | 1.11M | 2.82M | 11.41M | 1.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.34M | -6.06M | -4.29M | -2.05M |
| RepaymentOfDebt | -361.18K | -344.98K | -694.98K | 0.00 |
| IssuanceOfDebt | 191.85K | 0.00 | 1.28M | 3.51M |
| IssuanceOfCapitalStock | 4.35M | 0.00 | 6.03M | 0.00 |
| CapitalExpenditure | -79.08K | -22.90K | -219.99K | |
| InterestPaidSupplementalData | 17.61K | 37.12K | 2.46K | 0.00 |
| IncomeTaxPaidSupplementalData | 11.65K | 20.99K | 30.64K | 1.95K |
| EndCashPosition | 1.11M | 2.82M | 11.41M | 1.36M |
| BeginningCashPosition | 2.82M | 11.41M | 1.36M | 83.11K |
| ChangesInCash | -1.72M | -8.59M | 10.05M | 1.28M |
| FinancingCashFlow | 5.63M | -344.98K | 14.34M | 3.33M |
| CashFlowFromContinuingFinancingActivities | 5.63M | -344.98K | 14.34M | 3.33M |
| NetOtherFinancingCharges | -55.84K | -180.75K | ||
| ProceedsFromStockOptionExercised | 1.45M | 0.00 | 7.79M | 0.00 |
| NetCommonStockIssuance | 4.35M | 0.00 | 6.03M | 0.00 |
| CommonStockIssuance | 4.35M | 0.00 | 6.03M | 0.00 |
| NetIssuancePaymentsOfDebt | -169.33K | -344.98K | 584.16K | 3.51M |
| NetShortTermDebtIssuance | 0.00 | 299.00K | 3.29M | |
| ShortTermDebtPayments | 0.00 | -425.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 724.00K | 3.29M | |
| NetLongTermDebtIssuance | -169.33K | -344.98K | 285.17K | 212.26K |
| LongTermDebtPayments | -361.18K | -344.98K | -269.98K | 0.00 |
| LongTermDebtIssuance | 191.85K | 0.00 | 555.15K | 212.26K |
| InvestingCashFlow | -79.08K | -2.21M | -219.99K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -79.08K | -2.21M | -219.99K | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -2.19M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -2.19M | 0.00 | |
| NetPPEPurchaseAndSale | -79.08K | -22.90K | -219.99K | 0.00 |
| PurchaseOfPPE | -79.08K | -22.90K | -219.99K | 0.00 |
| OperatingCashFlow | -7.26M | -6.04M | -4.07M | -2.05M |
| CashFlowFromContinuingOperatingActivities | -7.26M | -6.04M | -4.07M | -2.05M |
| ChangeInWorkingCapital | 179.72K | 900.79K | 114.20K | 632.82K |
| ChangeInOtherWorkingCapital | -9.47K | 40.45K | ||
| ChangeInPayablesAndAccruedExpense | 631.43K | 347.51K | 621.46K | 667.81K |
| ChangeInAccruedExpense | 248.91K | 362.01K | 506.82K | 628.79K |
| ChangeInInterestPayable | 0.00 | 0.00 | 440.49K | 521.05K |
| ChangeInPayable | 382.52K | -14.50K | 114.64K | 39.02K |
| ChangeInAccountPayable | 382.52K | -14.50K | 114.64K | 39.02K |
| ChangeInPrepaidAssets | -105.59K | 214.40K | -492.75K | -34.99K |
| ChangeInInventory | -9.12K | -12.94K | -5.54K | 0.00 |
| ChangeInReceivables | -327.53K | 311.37K | -8.96K | 0.00 |
| OtherNonCashItems | 3.92M | -244.35K | ||
| StockBasedCompensation | 989.68K | 748.82K | 248.59K | 43.01K |
| DepreciationAmortizationDepletion | 605.64K | 249.59K | 10.18K | 4.82K |
| DepreciationAndAmortization | 605.64K | 249.59K | 10.18K | 4.82K |
| OperatingGainsLosses | -212.26K | 3.84M | ||
| GainLossOnInvestmentSecurities | 4.08M | |||
| NetIncomeFromContinuingOperations | -9.04M | -7.94M | -8.15M | -6.33M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BIAF
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|